Search Results for "vitamin B12"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vitamin B12. Results 1 to 7 of 7 total matches.
See also: Nascobal
Vonoprazan (Voquezna) for Nonerosive GERD
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
and toxic epidermal
necrolysis can occur with use of vonoprazan.
Vitamin B12 deficiency and hypomagnesemia ...
The potassium-competitive acid blocker vonoprazan
(Voquezna – Phathom), which was approved earlier
for treatment of erosive esophagitis, has now been
approved by the FDA for relief of heartburn associated
with nonerosive gastroesophageal reflux disease
(GERD) in adults. Vonoprazan is also available
copackaged with amoxicillin (Voquezna Dual Pak) and
with amoxicillin and clarithromycin (Voquezna Triple
Pak) for treatment of Helicobacter pylori infection.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):164-6 doi:10.58347/tml.2024.1713c | Show Introduction Hide Introduction
Comparison Table: H2-Receptor Antagonists and PPIs (online only)
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
, Clostridioides
difficile infection,
hypomagnesemia, vitamin
B12 deficiency, chronic
kidney disease ...
View the Comparison Table: H2-Receptor Antagonists and PPIs
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
in various strengths and in
combination with other agents, such as vitamin
B12, at a lower cost ...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Vonoprazan (Voquezna) for Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
and toxic epidermal necrolysis can occur
with use of vonoprazan. Vitamin B12 deficiency and
hypomagnesemia ...
The FDA has approved vonoprazan (Voquezna –
Phathom), a potassium-competitive acid blocker, for
healing and maintenance of healing of all grades of
erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged
with amoxicillin (Voquezna Dual Pak) and with
amoxicillin and clarithromycin (Voquezna Triple Pak)
for treatment of Helicobacter pylori infection in adults.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):203-5 doi:10.58347/tml.2023.1692b | Show Introduction Hide Introduction
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
in various strengths and in combination with other agents, such as vitamin B12, at a lower cost ...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight...
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
. Should be taken on an empty stomach.
including dementia, vitamin B12 deficiency, chronic
kidney disease ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
pain), possible vitamin B12 deficiency, rarely lactic acidosis
SGLT2 Inhibitors (canagliflozin ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.